Skip to main content

CytoSorbents Corporation (CTSO)

NASDAQ: CTSO · IEX Real-Time Price · USD
5.83 -0.21 (-3.48%)
Oct 22, 2021 4:00 PM EDT - Market closed
Market Cap258.70M
Revenue (ttm)45.13M
Net Income (ttm)-10.36M
Shares Out43.32M
EPS (ttm)-0.24
PE Ration/a
Forward PE106.38
Dividendn/a
Ex-Dividend Daten/a
Volume208,148
Open6.01
Previous Close6.04
Day's Range5.79 - 6.02
52-Week Range5.79 - 11.68
Beta0.41
AnalystsStrong Buy
Price Target12.67 (+117.3%)
Est. Earnings DateNov 4, 2021

About CTSO

Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of post-operative complications of cardiopulmonary bypass surgery, and maintainin...

IndustryHealth Care Equipment & Supplies
Founded1997
CEOPhillip Chan
Employees195
Stock ExchangeNASDAQ
Ticker SymbolCTSO
Full Company Profile

Financial Performance

In 2020, CytoSorbents's revenue was $41.00 million, an increase of 64.35% compared to the previous year's $24.95 million. Losses were -$7.84 million, -59.32% less than in 2019.

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for CytoSorbents stock is "Strong Buy." The 12-month stock price forecast is 12.67, which is an increase of 117.32% from the latest price.

Price Target
$12.67
(117.32% upside)
Analyst Consensus: Strong Buy

News

CytoSorbents Comments on REMOVE Study Presentation

MONMOUTH JUNCTION, N.J., Oct. 20, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using CytoS...

2 days ago - PRNewsWire

First Patient Enrolled in U.S. STAR-T Pivotal Trial Evaluating the DrugSorb-ATR™ Antithrombotic Removal System to Rem...

MONMOUTH JUNCTION, N.J., Oct. 14, 2021 /PRNewswire/ --  CytoSorbents Corporation  (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blo...

1 week ago - PRNewsWire

CytoSorbents Receives Full FDA Investigational Device Exemption (IDE) Approval to Begin U.S. STAR-D Trial on Apixaban...

MONMOUTH JUNCTION, N.J., Oct. 12, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood...

1 week ago - PRNewsWire

CytoSorbents Provides Preliminary Third Quarter Business Update and Revised 2021 Product Revenue Guidance

MONMOUTH JUNCTION, N.J., Oct. 12, 2021 /PRNewswire/ --  CytoSorbents Corporation  (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blo...

1 week ago - PRNewsWire

CytoSorbents Announces Availability of Preliminary Data Abstracts from Two Endocarditis Studies, including the REMOVE...

MONMOUTH JUNCTION, N.J., Oct. 7, 2021 /PRNewswire/ --  CytoSorbents Corporation  (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using bloo...

2 weeks ago - PRNewsWire

CytoSorbents to Host International Webinar on the Worldwide Experience Using CytoSorb® in Critically Ill Patients wit...

MONMOUTH JUNCTION, N.J., Sept. 14, 2021 /PRNewswire/ --  CytoSorbents Corporation  (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery announce...

1 month ago - PRNewsWire

A Trio of Stocks Growing Revenue Per Share Fast

The S&P 500 stocks saw their aggregate trailing 12-month real revenue per share grow at a compound annual growth rate of approximately 2.4% over the past five years. The share price of the benchmark ind...

Other symbols:EXRKE
1 month ago - GuruFocus

CytoSorbents Commemorates World Sepsis Day and Sepsis Awareness Month with Key Sepsis-Related Events, Sponsorships an...

MONMOUTH JUNCTION, N.J., Sept. 13, 2021 /PRNewswire/ --  CytoSorbents Corporation  (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions, such as sepsis, in intensive care and cardiac...

1 month ago - PRNewsWire

CytoSorbents Announces Filing of an Investigational Device Exemption (IDE) for the U.S. Clinical Trial on Apixaban an...

MONMOUTH JUNCTION, N.J., Sept. 10, 2021 /PRNewswire/ --  CytoSorbents Corporation  (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using bl...

1 month ago - PRNewsWire

CytoSorbents Announces Webinar Discussing Topline Results from the U.S. CTC Registry using CytoSorb® in Critically Il...

MONMOUTH JUNCTION, N.J., Sept. 8, 2021 /PRNewswire/ --  CytoSorbents Corporation  (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blo...

1 month ago - PRNewsWire

CytoSorbents' Product Associated With High Survival In Critically Ill COVID-19 Patients

CytoSorbents Corporation (NASDAQ: CTSO) has announced topline results from its CytoSorb Therapy in COVID-19 (CTC) multicenter registry. The data were presented at the International Symposium on Intensiv...

1 month ago - Benzinga

Topline Results from CytoSorbents' U.S. CTC Multicenter Registry Demonstrate High Survival using CytoSorb® in Critica...

MONMOUTH JUNCTION, N.J., Sept. 1, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood...

1 month ago - PRNewsWire

CytoSorbents, Aferetica Launch Organ Perfusion System In Italy

CytoSorbents Corporation (NASDAQ: CTSO) and Aferetica srl (Italy) have launched products to remove inflammatory mediators at Italy's European Society of Organ Transplantation Congress. Aferetica's PerLi...

1 month ago - Benzinga

CytoSorbents and Aferetica Announce the Commercial Launch in Italy of the PerSorb™ Adsorber and PerLife™ Organ Perfus...

MONMOUTH JUNCTION, N.J. and BOLOGNA, Italy, Aug. 30, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO) and Aferetica srl (Italy), two pioneers in intensive care immunotherapy and blood purifi...

1 month ago - PRNewsWire

CytoSorbents' Antithrombotic Removal System Scores Second FDA Breakthrough Device Tag

The FDA has granted a second Breakthrough Device designation to  CytoSorbents Corporation's (NASDAQ: CTSO) DrugSorb-ATR Antithrombotic Removal System.  The designation covers removing the Direct Oral An...

2 months ago - Benzinga

Second U.S. FDA Breakthrough Device Designation Granted to CytoSorbents' DrugSorb-ATR™ Antithrombotic Removal System ...

MONMOUTH JUNCTION, N.J., Aug. 12, 2021 /PRNewswire/ --  CytoSorbents Corporation  (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blo...

2 months ago - PRNewsWire

CytoSorbents Q2 Earnings Lag Consensus, Higher Costs Weigh On Bottom Line

CytoSorbents Corporation (NASDAQ: CTSO) reported Q2 revenue of $12 million, up 23% Y/Y, but missing the consensus of $12.27 million. Product sales increased 19% Y/Y to $11.4 million.

2 months ago - Benzinga

CytoSorbents Reports Second Quarter 2021 Financial and Operational Results

MONMOUTH JUNCTION, N.J., Aug. 3, 2021 /PRNewswire/ --  CytoSorbents Corporation  (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using bloo...

2 months ago - PRNewsWire

CytoSorbents Completes its Mission 100,000 International Fundraising Campaign to Fight the Spread of COVID-19 for Glo...

MONMOUTH JUNCTION, N.J., July 30, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood...

2 months ago - PRNewsWire

CytoSorbents to Report Second Quarter 2021 Operating and Financial Results

MONMOUTH JUNCTION, N.J., July 19, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO) a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery usi...

3 months ago - PRNewsWire

Here's Why Cytosorbents Is Up 17% Today

The biotech company took another step toward introducing a new way of performing bypass surgeries.

3 months ago - The Motley Fool

CytoSorbents Shares Are Trading Higher On Launch Of Trial On Ticagrelor Removal During Cardiothoracic Surgery

CytoSorbents Corporation (NASDAQ: CTSO) receives full FDA approval to conduct the STAR-T trial in the U.S. to support regulatory clearance of DrugSorb Antithrombotic Removal (ATR) system for intraoperat...

3 months ago - Benzinga

CytoSorbents Receives Full FDA Approval of Investigational Device Exemption (IDE) for U.S. STAR-T Trial on Ticagrelor...

MONMOUTH JUNCTION, N.J., July 6, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO) announces the full approval of its Investigational Device Exemption (IDE) application to conduct the pivotal...

3 months ago - PRNewsWire

CytoSorbents Appoints Terri Anne Powers, IRC as Vice President of Investor Relations and Corporate Communications

MONMOUTH JUNCTION, N.J., June 1, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care therapy leader commercializing its CytoSorb® blood purification technology to treat deadly ...

4 months ago - PRNewsWire

CytoSorbents to Present at the Jefferies Virtual Healthcare Conference

MONMOUTH JUNCTION, N.J., May 27, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care leader commercializing its CytoSorb® blood purification technology to treat deadly conditio...

4 months ago - PRNewsWire